Relative decreases in VP mean weights using VIN against TP controls in eight laboratories (Lab) by William Owens (20777)

Effect of specific inhibitors on CYP-mediated CK (50 μM) metabolism in HLMs. by Jian Xiao (253329)

Five compounds significantly decrease MAPK1 phosphorylation in K562 cells. by Pamela Y. Ting (713174)

Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

Subjects:

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

LY5 does not inhibit growth of <i>ex vivo</i> pulmonary metastasis. by Peter Y. Yu (4281448)

Average step length and frequency (± SEM) per 5% of the distance during normal and 3, 4, and 5 kg assisted 60 m sprints for men and women. by Roland van den Tillaar (6407390)

Blocking C5L2 decreased C5a-primed neutrophils for ANCA-induced respiratory burst. by Jian Hao (160736)

AA-deficient <i>sfx</i> mice had decreased articular cartilage. by Richard C. Lindsey (7148168)

Assays of TUNEL revealed a decreased number of apoptotic cell after oroxylin A treatment. by Shu-Fang Lin (4167091)

Type and duration of leisure-time activities performed 5 years after RYGB. by Alice Bellicha (3583493)

Juvenile demyelination induces a loss of functional autapses. by Sara Hijazi (21656615)

“…<p><b>A</b>. <i>Upper panel</i>. Example traces (average of 8 sweeps) of unitary autaptic inhibitory postsynaptic currents triggered by voltage steps from holding potential of -−70 mV to 0 mV in PV interneuron (fast inward Na+ currents were partially removed), which can be blocked by gabazine (gray). …”

An example of three consecutive accretive growth steps. by Nol Chindapol (103374)

Means and Cronbach’s alphas for 5C and VAX-measured vaccination attitudes over 12 months. by Allyson J. Gallant (9382396)

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects: